

APPENDIX 5:

VENOUS THROMBOEMBOLISM REVIEW TEMPLATE

Admission details

UR: _____ DOB: _____

Name: _____ Sex: _____

Initial surgery location (hospital): _____

Initial surgery admitting unit: _____

Readmission (if occurred) location: _____

Readmission unit: _____

Date of admission: _____ Date of discharge: _____

VTE prevention Standard risk assessment

VTE risk assessment documented? Y / N

Documented VTE plan in the notes? Y / N

Plan discussed with patient? Y / N / unknown

VTE risk factors and contraindications

Surgical procedure description and speciality: _____

ASA classification: _____ Duration of procedure (mins): _____

APPENDIX 5:

ADDITIONAL RISK FACTORS

(tick all that apply):

- | | |
|---|--|
| <input type="radio"/> Previous VTE | <input type="radio"/> Oestrogen containing HRT/oral contraceptive use (within 4 weeks) |
| <input type="radio"/> Diagnosed thrombophilia | <input type="radio"/> Heart failure or recent MI (<6 weeks) |
| <input type="radio"/> Active cancer (except skin lesions) | <input type="radio"/> Fibrinogen > 4g/l or platelets > 350*10 ⁹ /l |
| <input type="radio"/> Pregnancy and puerperium (within 6 weeks) | <input type="radio"/> Other |
| <input type="radio"/> Prolonged immobility (>4 days) | (describe): _____ |

MECHANICAL PROPHYLAXIS CONTRAINDICATION

(Describe): _____

Weight (kg): _____

Height (m): _____

PHARMACOLOGICAL PROPHYLAXIS CONTRAINDICATION OR COMPLICATING FACTOR

(tick all that apply):

- | | |
|---|---|
| <input type="radio"/> Inherited or acquired bleeding disorders (please describe) | <input type="radio"/> Other medications that may affect clotting (other anticoagulants) |
| <input type="radio"/> Severe platelet function disorder or thrombocytopaenia (<50 x 10 ⁹ /l) | <input type="radio"/> Severe renal dysfunction (eGFR <30) |
| <input type="radio"/> Recent CNS bleeding or CNS surgery (within 6 weeks) or risk of CNS bleeding | <input type="radio"/> Neuraxial blockade (spinal or epidural) |
| <input type="radio"/> Other perceived excessive surgical bleeding risk | <input type="radio"/> GI tract bleeding (active) |
| | <input type="radio"/> Other |
| | (describe): _____ |

APPENDIX 5:

VTE prevention methods used

MECHANICAL

Thromboembolic deterrent stockings (TEDS): Y / N / unknown

Sequential compression devices (SCD) intraop and while immobile: Y / N / unknown

PHARMACOLOGICAL

LMWH:

Preoperatively: Y / N

Timing if started intra or postoperatively (in hours from start of surgery):

Duration post op (days):

Dose per day:

Any missed doses: Y / N (reason if yes)

Rivaroxaban, dabigatran, apixaban:

Preoperatively: Y / N

Timing if started intra or postoperatively (in hours from start of surgery):

Duration (days):

Any missed doses: Y / N (reason if yes)

Unfractionated Heparin:

Preoperatively: Y / N

Timing if started intra or postoperatively (in hours from start of surgery):

Duration post op (days):

Dose per day:

Any missed doses: Y / N (reason if yes)

Warfarin:

Preoperatively: Y / N

Timing if started intra or postoperatively (in hours from start of surgery):

Duration (days):

Any missed doses: Y / N (reason if yes)

Target INR reached on post-operative day number:

Any subsequent sub-target INRs: Y/N

APPENDIX 5:

Ongoing postoperative management

VTE plan reassessed at seven days? Y / N / unknown

Discharged on anticoagulant: Y / N

Duration of prophylaxis post discharge: Days

VTE prevention discharge plan documented? Y / N / unknown

Patient informed of discharge plan? Y / N / unknown

Ongoing clinical provider informed? Y / N / unknown

Initial perioperative team aware of VTE Y / N

Discussed in M&M Y / N

If yes, which M&M (e.g. surgical, anaesthesia):

Potentially modifiable factors: Y / N

If yes, please describe:

References

Wickham, N., Gallus, A. S., Walters, B. N. J., Wilson, A., the NHMRC VTE Prevention Guideline Adaptation Committee. (2012). Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. *Internal Medicine Journal*, 42(6), 698–708. <http://doi.org/10.1111/j.1445-5994.2012.02808.x>

Chahal, R., Alexander, M., Yee, K., Jun, C. M. K., Dagher, J. G., Ismail, H., et al. (2020). Impact of a risk-stratified thromboprophylaxis protocol on the incidence of postoperative venous thromboembolism and bleeding. *Anaesthesia*, 90, 678–11. <http://doi.org/10.1111/anae.15077>

Australian Commission on Safety and Quality in Health Care. Venous Thromboembolism Prevention Clinical Care Standard January 2020, 1–56.